Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of BPD.

about

Anti-VEGF Antagonists, a Potential Primary Prevention for Bronchopulmonary Dysplasia?A Pathogenic Relationship of Bronchopulmonary Dysplasia and Retinopathy of Prematurity? A Review of Angiogenic Mediators in Both Diseases.

P2860

Q49340492-90E19216-A120-4431-8F80-48D3A28CB0CD Q55293851-4A31B9A6-33D4-49FF-B135-9E18A087E5B4

P2860

Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of BPD.

Item

http://www.wikidata.org/entity/Q48560810

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Anti-sFlt-1 Therapy Preserves ...... th in Antenatal Models of BPD.

@en

Anti-sFlt-1 Therapy Preserves ...... th in Antenatal Models of BPD.

@nl

type

Item

label

Anti-sFlt-1 Therapy Preserves ...... th in Antenatal Models of BPD.

@en

Anti-sFlt-1 Therapy Preserves ...... th in Antenatal Models of BPD.

@nl

prefLabel

Anti-sFlt-1 Therapy Preserves ...... th in Antenatal Models of BPD.

@en

Anti-sFlt-1 Therapy Preserves ...... th in Antenatal Models of BPD.

@nl

P1476

Anti-sFlt-1 Therapy Preserves ...... th in Antenatal Models of BPD.

@en

P2093

Amelie Peisl

http://www.w3.org/2001/XMLSchema#string

Bradley Wallace

http://www.w3.org/2001/XMLSchema#string

Christina Kim

http://www.w3.org/2001/XMLSchema#string

Dennis Keefe

http://www.w3.org/2001/XMLSchema#string

Gregory Seedorf

http://www.w3.org/2001/XMLSchema#string

Jennifer Bosco

http://www.w3.org/2001/XMLSchema#string

Jon Kenniston

http://www.w3.org/2001/XMLSchema#string

Steven H Abman

http://www.w3.org/2001/XMLSchema#string

Taylor Nowlin

http://www.w3.org/2001/XMLSchema#string

P2860

Bronchopulmonary dysplasia

Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use.

Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.

Chronic lung disease in the preterm infant. Lessons learned from animal models

Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation

Bronchopulmonary dysplasia: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases

Placental pathologic changes of maternal vascular underperfusion in bronchopulmonary dysplasia and pulmonary hypertension

P31

scholarly article

P356

10.1164/RCCM.201707-1371OC

http://www.w3.org/2001/XMLSchema#string

P407

English

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29268623

http://www.w3.org/2001/XMLSchema#string

P932

5855071

http://www.w3.org/2001/XMLSchema#string

Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of BPD.

about

P2860

P2860

Anti-sFlt-1 Therapy Preserves Lung Alveolar and Vascular Growth in Antenatal Models of BPD.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P407

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P407

P577

P698

P932